stocks have maintained market pace so far this year, rising 7.5% while
has risen 11.7% and the S&P 500 health sector index has gained 7.7%. The next indications of whether this can continue will come on Tuesday.
must disclose its final financial results before trading. A conference call with analysts and investors is scheduled for 10 a.m. Eastern Time.
Against the backdrop of the pandemic, Pfizer completed a long transformation that released dozens of subsidiaries to focus entirely on the development and acquisition of new drugs. The company says the success of the widely used Covid-19 vaccine has proven the viability of this new model.
Still, Pfizer shares are lagging behind the S&P 500 in the long run. Pfizer has grown by 6% since the beginning of 2020, while the S&P 500 has grown by 30.2%. Meanwhile, the two biotechnologies with Covid-19 vaccines, BioNTech (BNTX) and Moderna (MRNA), increased by 495% and 854%, respectively, over the same period.
Johnson and Johnson
(AZN), the other major pharmaceutical company with the Covid-19 vaccines on the market, Pfizer says it is selling its vaccine at a profit. But investors have not appreciated much appreciation for those vaccine sales, which the company says will generate $ 15 billion in revenue this year.
Pfizer traded 12.4 times the expected profit over the next 12 months, slightly below the 5-year average for 12.6 times, according to FactSet.
Here is a picture of investors’ expectations and recent history.
– Analysts expect Pfizer to report earnings of $ 0.78 per share and sales of $ 13.7 billion, according to a consensus estimate by FactSet.
– Pfizer reported earnings of $ 0.42 per share for the fourth quarter of 2020 in February, falling short of FactSet’s consensus estimates of $ 0.50 per share and $ 11.7 billion in sales.
– Pfizer’s revenue report comes after a difficult week for big profits from biopharma.
Bristol Myers Squib
(LLY) all had disappointing results.
(ABBV) has become a rare positive surprise among high-capitalization biopharmaceutical companies.
– More than 130 million doses of Pfizer and BioNTech’s Covid-19 vaccine have been administered in the United States, according to the Centers for Disease Control and Prevention, and more than 162 million doses have been delivered to local authorities.
– On Friday, Pfizer and BioNTech said they had asked regulators in the European Union to extend their conditional authorization for their Covid-19 vaccine to allow its use in adolescents aged 12 to 15 years. Taking medication on April 9.
– Also on Friday, Reuters reported that Pfizer begins exporting doses of its Covid-19 vaccine, produced in the United States
Adjustments and amplifications: The S&P 500 and S&P 500 in the healthcare sector are up 11.7% and 7.7% respectively this year. An earlier version of this article misrepresented their results.
Write to Josh Nathan-Kazis at firstname.lastname@example.org